Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum Uric Acid Levels and Renal Function in Untreated Hypertensive Patients.

Cureus·2026
Same author

Altered HDL Phospholipid and Fatty Acid Profile in MASLD: A Possible Explanation for the Increased CVD Risk.

International journal of molecular sciences·2025
Same author

The Effect of Low, Moderate, and High Doses of Rosuvastatin on Lipoprotein(a) Levels in Hyperlipidemic Patients with Impaired Fasting Glucose: A Post-Hoc Analysis.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2025
Same author

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?

Life (Basel, Switzerland)·2024
Same author

Extra Virgin Olive Oil and Metabolic Diseases.

International journal of molecular sciences·2024
Same author

Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study.

Expert opinion on pharmacotherapy·2024

Related Experiment Video

Updated: Jun 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pleiotropic effects of ezetimibe: do they really exist?

Michalis Kalogirou1, Vasilis Tsimihodimos, Moses Elisaf

  • 1Department of Internal Medicine, University of Ioannina, Ioannina, Greece.

European Journal of Pharmacology
|February 16, 2010
PubMed
Summary

Ezetimibe effectively lowers LDL cholesterol but its cardiovascular benefits are unclear. This review explores potential pleiotropic effects beyond cholesterol reduction, such as impacts on inflammation and endothelial function.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: Jun 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

  • Pharmacology and Cardiovascular Medicine

Background:

  • Ezetimibe is a lipid-lowering drug that inhibits cholesterol absorption.
  • It effectively reduces low-density lipoprotein cholesterol (LDL-C) when used alone or with statins.
  • Recent studies (ENHANCE, SEAS) did not show significant cardiovascular outcome benefits, questioning its clinical utility.

Purpose of the Study:

  • To review the potential pleiotropic effects of ezetimibe.
  • To investigate ezetimibe's impact on inflammation markers, lipoprotein subfractions, and endothelial function.
  • To explore possible explanations for the lack of observed cardiovascular benefits in clinical trials.

Main Methods:

  • Literature review of studies investigating ezetimibe's non-lipid-lowering effects.
  • Analysis of data on ezetimibe's influence on inflammatory markers.
  • Examination of studies assessing changes in lipoprotein subfractions.
  • Review of research on ezetimibe's effects on endothelial function.

Main Results:

  • Ezetimibe's primary mechanism is cholesterol absorption inhibition.
  • Evidence for significant pleiotropic effects, such as anti-inflammatory or endothelial benefits, is limited or inconclusive.
  • The lack of pleiotropic actions may contribute to the absence of demonstrated cardiovascular mortality benefits.

Conclusions:

  • Ezetimibe effectively lowers LDL-C but may lack beneficial pleiotropic effects.
  • Further research is needed to fully elucidate ezetimibe's impact on inflammation, lipoprotein profiles, and vascular health.
  • The clinical significance of ezetimibe's potential pleiotropic actions requires further investigation.